BERLIN--(Marketwire - August 17, 2012) -
MagForce AG /
MagForce AG: Dr. Jan zur Hausen elected to the Supervisory Board of
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Renowned life sciences and investment banking expert strengthens the
company's Supervisory Board
MagForce AG (Frankfurt, XETRA: MF6), a
leading medical device company in the field of nanomedicine with
oncology, announced today that Dr. Jan zur Hausen was unanimously elected
company's Supervisory Board at yesterday's Annual General Meeting. He is
over from Dr. Stefan Elßer, who resigned effective as of the end of
Dr. Jan zur Hausen (born in 1965) is a managing shareholder of
Hausen & Cie. GmbH, a corporate finance company that evolved from
Oppenheim's investment banking activities. While at Sal. Oppenheim,
Hausen was responsible for numerous transactions in the life sciences
Senior Vice President and Head of Healthcare.
Dr. zur Hausen has in-depth knowledge of health sciences and investment
He has a degree in biology, gained a Ph.D. in cell biology from the
of Basel, and previously worked at Hoffmann-La Roche, MPM Capital,
BioCapital, and DVC Deutsche Venture Capital, among others.
Dr. zur Hausen has known MagForce for many years now. "Dr. zur Hausen
excellent addition to the Supervisory Board thanks to his many years'
in the areas of both life sciences and investment banking. We see his
as offering strong support for our current corporate strategy,"
Andreas Jordan, Executive Board of MagForce AG. "We are convinced
expertise will enable him to provide us with important advice as we
our path and we would like to thank Dr. Elßer, who worked
MagForce for many years, for resigning from the Supervisory Board and
this step possible."
"I am looking forward to the challenges at MagForce AG and to my new
said Dr. Jan zur Hausen following his election. "MagForce is going
difficult period at the moment, but it is on the right track. I hope that I
be able to make a positive contribution to the company's future
About MagForce AG
MagForce AG is a leading medical technology company in the field of
in oncology. The Company's proprietary NanoTherm® therapy enables
treatment of solid tumors through the intratumoral generation of
activation of magnetic nanoparticles. NanoTherm®,
NanoActivator™ are components of the therapy and have received
regulatory approval as medical devices for the treatment of brain
MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of
in selected countries. For more information, please visit www.magforce.com.
This release may contain forward-looking statements and information that
identified by formulations using terms such as "expects", "aims",
"intends", "plans", "believes", "seeks", "estimates", or "will". Such
forward-looking statements are based on our current expectations
assumptions, which may be subject to a variety of risks and
results actually achieved by MagForce AG may differ substantially from
forward-looking statements. MagForce AG assumes no obligation to update
forward-looking statements or to correct them in case of developments
from those anticipated.
MagForce_Press Release_Jan zur Hausen_Aug 17, 2012:
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE